Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.
O'Connell CL, Baer MR, Ørskov AD, Saini SK, Duong VH, Kropf P, Hansen JW, Tsao-Wei D, Jang HS, Emadi A, Holmberg-Thyden S, Cowland J, Brinker BT, Horwood K, Burgos R, Hostetter G, Youngblood BA, Hadrup SR, Issa JP, Jones P, Baylin SB, Siddiqi I, Grønbaek K. O'Connell CL, et al. Among authors: youngblood ba. Clin Cancer Res. 2022 Dec 15;28(24):5306-5316. doi: 10.1158/1078-0432.CCR-22-1810. Clin Cancer Res. 2022. PMID: 36222848 Free PMC article. Clinical Trial.
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.
Baer MR, Kogan AA, Bentzen SM, Mi T, Lapidus RG, Duong VH, Emadi A, Niyongere S, O'Connell CL, Youngblood BA, Baylin SB, Rassool FV. Baer MR, et al. Among authors: youngblood ba. Clin Cancer Res. 2022 Apr 1;28(7):1313-1322. doi: 10.1158/1078-0432.CCR-21-3729. Clin Cancer Res. 2022. PMID: 35091444 Free PMC article. Clinical Trial.
Conserved epigenetic hallmarks of T cell aging during immunity and malignancy.
Mi T, Soerens AG, Alli S, Kang TG, Vasandan AB, Wang Z, Vezys V, Kimura S, Iacobucci I, Baylin SB, Jones PA, Hiner C, Mueller A, Goldstein H, Mullighan CG, Zebley CC, Masopust D, Youngblood B. Mi T, et al. Nat Aging. 2024 Aug;4(8):1053-1063. doi: 10.1038/s43587-024-00649-5. Epub 2024 Jun 12. Nat Aging. 2024. PMID: 38867059 Free PMC article.
Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy.
Kang TG, Lan X, Mi T, Chen H, Alli S, Lim SE, Bhatara S, Vasandan AB, Ward G, Bentivegna S, Jang J, Spatz ML, Han JH, Schlotmann BC, Jespersen JS, Derenzo C, Vogel P, Yu J, Baylin S, Jones P, O'Connell C, Grønbæk K, Youngblood B, Zebley CC. Kang TG, et al. Science. 2024 Oct 11;386(6718):eadl4492. doi: 10.1126/science.adl4492. Epub 2024 Oct 11. Science. 2024. PMID: 39388542
Improving antitumor T cells.
Zebley CC, Youngblood B. Zebley CC, et al. Science. 2022 Nov 11;378(6620):598. doi: 10.1126/science.adf0546. Epub 2022 Nov 10. Science. 2022. PMID: 36356156
Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL.
Talleur AC, Qudeimat A, Métais JY, Langfitt D, Mamcarz E, Crawford JC, Huang S, Cheng C, Hurley C, Madden R, Sharma A, Suliman A, Srinivasan A, Velasquez MP, Obeng EA, Willis C, Akel S, Karol SE, Inaba H, Bragg A, Zheng W, Zhou SM, Schell S, Tuggle-Brown M, Cullins D, Patil SL, Li Y, Thomas PG, Zebley C, Youngblood B, Pui CH, Lockey T, Geiger TL, Meagher MM, Triplett BM, Gottschalk S. Talleur AC, et al. Blood Adv. 2022 Nov 8;6(21):5737-5749. doi: 10.1182/bloodadvances.2021006293. Blood Adv. 2022. PMID: 35446934 Free PMC article. Clinical Trial.
Cell-Intrinsic Barriers of T Cell-Based Immunotherapy.
Ghoneim HE, Zamora AE, Thomas PG, Youngblood BA. Ghoneim HE, et al. Among authors: youngblood ba. Trends Mol Med. 2016 Dec;22(12):1000-1011. doi: 10.1016/j.molmed.2016.10.002. Epub 2016 Nov 4. Trends Mol Med. 2016. PMID: 27825667 Free PMC article. Review.
98 results